ReviewCurrent allergy and asthma reports2015
Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 74 citations in OpenAlex.
- Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M).JNCI cancer spectrum · 2022Trial
- Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2018Trial
- Rapid Drug Desensitization to Platinum-based Chemotherapy Agents: A Single-center Experience.Thoracic research and practice · 2026Article
- Current status of carboplatin desensitization therapy for gynecologic malignancies.Journal of gynecologic oncology · 2026Review
- Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004.Gynecology and pelvic medicine · 2025Article
- Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking FeJournal of nanobiotechnology · 2024Article
- Article
- Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.International journal of molecular sciences · 2023Review
- Interdisciplinary Healthcare Team Experience of Carboplatin and Oxaliplatin Desensitizations in a Tertiary Referral University Hospital.Journal of asthma and allergy · 2023Article
- Successful desensitization after hypersensitivity reaction to cisplatin in a patient with nasopharyngeal carcinoma.Clinical case reports · 2022Article
- Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement.The World Allergy Organization journal · 2022Review
- Omalizumab for successful chemotherapy desensitisation: What we know so far.Clinical and translational allergy · 2021Review
- Article
- Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.Current allergy and asthma reports · 2021Review
- Nanoallergen platform for detection of platin drug allergies.The Journal of allergy and clinical immunology · 2019Article
- Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.Oncology letters · 2019Article
- Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.Journal of asthma and allergy · 2018Review
- Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.Medicine · 2017Article
- Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial StudyAsian Pacific journal of cancer prevention : APJCP · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity reactions (HSRs) to platinum drugs are increasing due to their extensive use in a wide variety of malignancies and the repeated exposures in patients with increased life expectancy. Understanding the incidence of HSR to platinum drugs and associated risk factors can help with the diagnosis and may provide protection against severe HSRs. A thorough clinical history with identification of the typical and atypical symptoms, the relationship with the platin administration, and the number of previous exposures are the key to the diagnosis. An elevated serum tryptase at the time of the HSR indicates that IgE and/or mast cells/basophils were involved in the HSR. Skin testing to platinum drugs is a highly sensitive and specific diagnostic tool, which helps provide risk stratification and management recommendations. Platinum specific IgE measurement and basophil activation test (BAT) are emerging as new diagnostic tools and in combination with skin testing can help support the diagnosis and the cross-reactivity between the three most commonly used platinum drugs, namely carboplatin, cisplatin, and oxaliplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.